HC Wainwright Predicts Weaker Earnings for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Equities research analysts at HC Wainwright lowered their FY2024 earnings per share estimates for Dyne Therapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($3.55) per share for the year, down from their prior estimate of ($3.06). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2024 earnings at ($1.04) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at $0.19 EPS.

A number of other research analysts have also recently commented on DYN. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Morgan Stanley increased their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Piper Sandler restated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $28.39 on Monday. Dyne Therapeutics has a 1-year low of $9.76 and a 1-year high of $47.45. The stock has a market cap of $2.89 billion, a P/E ratio of -7.97 and a beta of 1.10. The stock’s 50 day simple moving average is $32.48 and its 200-day simple moving average is $35.24.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25).

Insiders Place Their Bets

In other news, CEO John Cox bought 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. This represents a -133.33 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares of the company’s stock, valued at $3,522,698.20. The trade was a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,975 shares of company stock worth $5,693,789. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC boosted its position in shares of Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after buying an additional 352 shares during the period. Nisa Investment Advisors LLC grew its position in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after buying an additional 709 shares during the period. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the period. Finally, Amalgamated Bank grew its holdings in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.